Pulmonary infection is a common complication after lung transplantation, and early detection is crucial for outcome. However, the condition can be clinically difficult to diagnose and to distinguish from rejection. The aim of this prospective study was to evaluate 
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STJÄRNE ASPELUND ET AL. can therefore be difficult to distinguish clinically. However, Lntx patients may lack classical signs of infection due to heavy immunosuppression, and rejection may be asymptomatic. In addition, there are possible links between infection and the development of rejection. 4 For example, viral pneumonia has been associated with chronic lung allograft dysfunction and graft loss. 5 Moreover, growth of bacteria or fungi in bronchoalveolar lavage fluid (BALF) cultures does not always represent infection, as bacterial and fungal colonization of the transplanted lung is common. Infections with multidrug-resistant bacteria pose an increasing threat to solid organ transplant recipients, and the discrimination between infection and colonization is important before starting long-term treatment of resistant bacteria with the possible side effects and interactions. 6 Antimicrobial peptides in respiratory secretions play an important role as a first line of defence against infections. 7 Lysozyme is the most abundant airway antimicrobial peptide, and is secreted primarily by neutrophils and sub-mucosal glands. 8 Heparin-binding protein (HBP) was initially recognized for its broad antimicrobial activity, but is now known to be a multifunctional inflammatory mediator that induces vascular leakage and acts as a chemoattractant and activator of monocytes. 9, 10 The protein is stored in secretory and azurophilic granules of neutrophils, and is rapidly released upon cell activation. 11 Plasma HBP has been described as a promising biomarker for severe sepsis and septic shock, 12 and elevated HBP levels have also been shown in cerebrospinal fluid during bacterial meningitis 13 and in urine during urinary tract infections. 14 Neither HBP nor lysozyme has previously been evaluated in BALF of Lntx patients. In this study, we quantified the two proteins together with the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, IL-8 and TNF, and anti-inflammatory IL-10 in BALF collected during the first year after transplantation. The primary aim was to evaluate HBP and lysozyme as potential biomarkers for infection, and to determine their ability to discriminate infection from rejection in lung transplant recipients.
| MATERIAL AND METHODS

| Study setting and patient population
This prospective cohort study was conducted at Skåne University Hospital, one of two centers in Sweden that performs Lntx. Adult patients accepted for Lntx during the study period from October 2012
to December 2014 were eligible for inclusion. Patients younger than 18 years of age and patients with postoperative follow-up at other sites were excluded. All study participants were followed for a maximum of 1 year after transplantation. Written informed consent was obtained from all study patients. The study was approved by the regional ethics committee (Reg nr 433-08) and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Standard protocol for immune suppression included induction therapy with ATG (anti-thymocyte globulin), followed by tacrolimus or cyclosporine, mycophenolate mofetil, and steroids. All Lntx recipients were treated with cytomegalovirus and fungal prophylaxis for 3-6 months. 
| Sample collection
| Grading of infection
The likelihood of pulmonary infection at the time of BALF sampling was independently, and blinded to the results of the biomarkers, 
| Analysis of HBP, lysozyme, and cytokines
HBP concentrations were analyzed with enzyme-linked immunosorbent assay (ELISA) as described previously. 
| Statistical analysis
Chi-square, rank sum, Kruskal-Wallis, and Mann-Whitney U tests were used to assess the distribution of biomarker levels between the different groups of probability of infection (no infection, possible, probable, and definite infection) and rejection. Receiver-operating characteristic (ROC) analyses were used to assess the diagnostic power of each biomarker for infection, dichotomized into probable/definite infection as compared to no or possible infection and rejection and the areas under the ROC curve (AUCs) were compared. Sensitivity, specificity, and positive and negative predictive values were calculated based on cut-off levels identified in the ROC analyses that maximized sensitivity and specificity.
Using logistic regression, we calculated odds ratios (ORs) for infection (dichotomized into definite and probable vs no or possible infection and rejection) for each biomarker. We used generalized estimating equation (GEE) models to account for the possibility of dependency due to multiple observations from the same patient.
The different biomarkers were first analyzed in univariable models and secondly in models adjusted for time after Lntx. All statistical tests were two-sided, and 95% confidence intervals (CIs) that did not overlap 1.0 and P values <.05 were considered statistically significant. Analyses were performed using STATA/SE (version 13. 
| RESULTS
| Patient cohort
In total, 39 patients were transplanted during the study period. Five patients were not eligible for inclusion due to follow-up at another center, and one patient declined participation. Consequently, 33 patients were included in the study. Four participants died shortly after transplantation, before any study samples were collected, leaving 29 lung transplant recipients prospectively followed in this study. The patients, 12 women and 17 men, had a median age of 56 years, 86% underwent double lung transplantation, and cystic fibrosis was the most common underlying disease. For details on patient characteristics, see Table 2 . 
T A B L E 1 Grading of infection and rejection
| Grading of infection and rejection
Patients were assessed for infection at the time of BAL as described in Table 1 . Twenty-one BALF samples were graded as no infection, 15 BALF samples as possible infection, 38 BALF samples as probable infection, and 23 BALF samples were classified as definite infection ( Figure 1 ). Among the samples graded as probable infection, 7 patients with 9 BALF samples were asymptomatic at the time of BAL.
All had growth of bacteria and macroscopic endobronchial signs of infection. Four of 7 patients also presented new infiltrates on chest radiograph.
Bacterial growth was detected in 54 BALF samples (48%).
Pseudomonas aeruginosa was the most commonly isolated bacterial species (12%), followed by Escherichia coli (9%). Thirty-eight samples (35%) had fungal growth, with Candida albicans and Aspergillus fumigatus being the dominating fungal organisms (17% and 6%, respectively).
Eighteen ( At an HBP cut-off value of 150 ng/mL, sensitivity was 75% and specificity was 92% for the detection of infection; positive predictive value (PPV) and negative predictive value (NPV) were 92% and 76%, respectively. IL-1β and IL-8 performed similar to HBP, whereas lysozyme showed poor sensitivity and specificity (Table 3) .
T A B L E 2 Patient characteristics
Total number of patients (n) 29
Age (median range) 56 Gender n (%)
Female
(41)
Male
(59)
Underlying disease n (%)
Cystic fibrosis 7 (24)
Lung fibrosis 5 (17)
Alfa-1-antitrypsin deficiency 3 (10)
Pulmonary arterial hypertension 3 (10)
Bronchiolitis obliterans syndrome 2 (7)
Sarcoidosis
(3)
Lung graft vs host reaction 1 (3)
Single n (%) 3 (10) Heart and Lung n (%) 1 (3)
COPD, chronic obstructive pulmonary disease. To account for the possibility of bias due to multiple samples from the same individual, and to adjust for time after transplantation, we used generalized estimating equation (GEE) models. Using GEE analyses, the estimated ORs for the prediction of definite and probable infection as compared to no or possible infection and rejection, were 32 (95% CI 9-112) for HBP, 17 (95% CI 6-48) for IL-1β, 17 (95% CI 6-46) for IL-8, and 4 (95% CI 2-8) for lysozyme; at set cut-offs.
| DISCUSSION
In this prospective study on lung transplant recipients comparing different biomarkers for prediction of infection, we found that HBP, IL-1β, and IL-8 were the best BALF biomarkers of infection. Samples from patients with TBB-verified rejection had low levels of all tested biomarkers, with concentrations in the same range as noninfection samples.
Neutrophils are recruited to the airways in response to infection, and increased neutrophil numbers are found in BALF during bacterial infection. 18 Neutrophil counts were not analyzed in this study, which is a major shortcoming given that both HBP and lysozyme are re- anti-inflammatory properties but showed the same pattern as the pro-inflammatory cytokines in this study. IL-10 is believed to play an important role in balancing the inflammatory response in order to limit host tissue damage. 19 For example, compared to wild-type mice, IL-
10-deficient mice demonstrate more efficient bacterial clearance but higher mortality and increased neutrophil recruitment to the lung in response to Streptococcus pneumoniae infection, 20 which underscores the regulatory role of IL-10 during infection. It could therefore be speculated that IL-10 increases simultaneously with pro-inflammatory cytokines in order to avoid excessive inflammation that would be harmful to the host.
To correct for dilution factors of BALF, we used the urea method as shown that IL-1β and IL-8 in BALF are potential markers of ventilatorassociated pneumonia (VAP), 21 which further strengthens their utility as biomarkers.
In this study, we found no significant differences in levels between rejection and noninfection for any of the biomarkers. Contrary to our results, Patella et al have demonstrated increased levels of IL-10 during rejection compared to no rejection. 22 One possible reason for this discrepancy is that rejection is defined differently in the two studies. Here, we identify rejection with TBB to ensure correct diagnosis. All tested biomarkers have in common that they indicate neutrophil-dominated inflammation. In contrast, rejection is primarily a T cell-driven process, 23 which may explain why none of the markers in this study were elevated in this group. However, the distinction is difficult as infection can drive rejection, and TBB staging can also be false positive in the presence of infection. In our study, all but two patients with rejection had repeated positive TBBs, which increases the likelihood of true results.
Most infections are reported to occur within the first 3 months after Lntx, especially those of bacterial origin. 24 In our study, we noted a tendency toward a decreasing risk of infection with time after transplantation. However, the total risk of infection has not been assessed in this study, as infections occurring between bronchoscopies may have been missed and cultures from sputum and other locations were not considered. We chose to define infection as samples graded probable and definite infection in our calculations. We believe this is appropriate in this clinical setting with immunocompromised patients where treatment of a probable infection would be justified.
This was a single-center study with a limited number of patients, which is a shortcoming to our study. Second, even if efforts were made to have a standardized protocol for BAL procedure and study sampling, we cannot fully estimate the dilution factor. However, with the described urea method we have tried to address this problem.
Another difficulty was the definition of infection in these patients. We 
